HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacological prolyl hydroxylase domain inhibition as a therapeutic target for Parkinson's disease.

Abstract
Previously published data from our laboratory demonstrated that pharmacological inhibition of a family of enzymes known as prolyl hydroxylase domain proteins prevents neurotoxicity associated with the acute 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine intoxication model of Parkinson's disease in young animals. In this study, we assessed whether prolyl hydroxylase domain inhibition was neuroprotective in an inducible genetic dopaminergic glutathione depletion model previously characterized by our laboratory that more closely recapitulates the age-related and progressive nature of the human disease. Pharmacological prolyl hydroxylase domain inhibition via 3,4-dihydroxybenzoate was found to significantly attenuate hallmark mitochondrial dysfunction and loss of dopaminergic substantia nigral pars compacta neurons associated with this model. These studies further validate the possibility that prolyl hydroxylase domain inhibition may constitute a viable therapy for Parkinson's disease.
AuthorsSubramanian Rajagopalan, Shankar J Chinta, Julie K Andersen
JournalCNS & neurological disorders drug targets (CNS Neurol Disord Drug Targets) Vol. 13 Issue 1 Pg. 120-5 (Feb 2014) ISSN: 1996-3181 [Electronic] United Arab Emirates
PMID24040809 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3,4-dihydroxybenzoate
  • Enzyme Inhibitors
  • Hydroxybenzoates
  • Prolyl-Hydroxylase Inhibitors
  • Buthionine Sulfoximine
  • Prolyl Hydroxylases
  • Glutathione
Topics
  • Age Factors
  • Analysis of Variance
  • Animals
  • Buthionine Sulfoximine (toxicity)
  • Cell Line, Transformed
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (toxicity)
  • Glutathione (genetics)
  • Hydroxybenzoates (therapeutic use)
  • Mass Spectrometry
  • Mice
  • Mice, Transgenic
  • Mitochondria (drug effects, metabolism)
  • Oxygen Consumption (drug effects)
  • Parkinson Disease (drug therapy, genetics, metabolism)
  • Prolyl Hydroxylases (metabolism)
  • Prolyl-Hydroxylase Inhibitors (therapeutic use)
  • Rats
  • Substantia Nigra (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: